MARKET

CBIO

CBIO

Crescent Biopharma Inc
NASDAQ
11.75
-1.06
-8.24%
After Hours: 11.98 +0.24 +2.00% 17:54 07/15 EDT
OPEN
12.80
PREV CLOSE
12.80
HIGH
13.04
LOW
11.51
VOLUME
180.67K
TURNOVER
--
52 WEEK HIGH
63.00
52 WEEK LOW
11.06
MARKET CAP
163.17M
P/E (TTM)
-0.2569
1D
5D
1M
3M
1Y
5Y
1D
Crescent Biopharma Inc. Files Initial Statement of Beneficial Ownership: Jan Pinkas, Chief Scientific Officer
Reuters · 21h ago
Crescent Biopharma Price Target Announced at $27.00/Share by Wedbush
Dow Jones · 2d ago
Wedbush Initiates Coverage On Crescent Biopharma with Outperform Rating, Announces Price Target of $27
Benzinga · 2d ago
Weekly Report: what happened at CBIO last week (0707-0711)?
Weekly Report · 2d ago
Crescent Biopharma initiated with an Outperform at Wedbush
TipRanks · 2d ago
Crescent Biopharma appoints Jan Pinkas as CSO
TipRanks · 07/08 11:36
CRESCENT BIOPHARMA APPOINTS JAN PINKAS, PH.D., AS CHIEF SCIENTIFIC OFFICER
Reuters · 07/08 11:30
Press Release: Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer
Dow Jones · 07/08 11:30
More
About CBIO
Crescent Biopharma Inc., formerly GlycoMimetics, Inc., is a biotechnology company. The Company is engaged in advancing novel precision-engineered molecules to advance care for patients with solid tumors. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads for undisclosed targets. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.

Webull offers Crescent Biopharma Inc stock information, including NASDAQ: CBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CBIO stock methods without spending real money on the virtual paper trading platform.